Radiation and immunotherapy join forces against hard-to-treat liver cancer
NCT ID NCT05705791
First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time
Summary
This trial tests whether adding a precise, internal radiation treatment (166Holmium microspheres) to standard immunotherapy (atezolizumab and bevacizumab) can shrink liver tumors that cannot be surgically removed. About 10 adults with unresectable hepatocellular carcinoma will receive the combination and be followed for up to a year. The main goal is to see how many patients have a complete or partial response within 6 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- 166Holmium microspheres (QuiremSpheres) plus atezolizumab and bevacizumab
- What this could lead to
- If successful, this combination could offer a more effective treatment option for people with liver cancer that cannot be removed by surgery.
- What could go wrong
- This is a very small early-phase trial with only 10 participants, so results may not apply broadly. The added radiation carries risks like liver damage or other side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AP-HP Hôpital Beaujon
Clichy, 92110, France
-
CHU François Mitterand
Dijon, 21000, France
-
CHU Nantes
Nantes, 44000, France
-
Centre Georges-François Leclerc
Dijon, 21000, France
-
Gustave Roussy
Villejuif, 94800, France
-
Hôpital Saint Eloi
Montpellier, 34000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a cancer vaccine prime the body to better fight liver tumors?
- Training the immune system to hunt down leftover liver cancer cells
- Can a new drug ST316 shrink Hard-to-Treat tumors?
- Could a genetic marker guide future cancer therapies in taiwan?
- Can a tumor-zapping procedure also wake up the immune system?
- A machine that keeps donor livers alive outside the body — could it transform transplantation?